{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:09:52Z","timestamp":1790546992030,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010580","name":"Department of Science and Technology, Hubei Provincial People's Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010580","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.antiviral.2020.104868","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T11:25:07Z","timestamp":1594380307000},"page":"104868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Immunoglobulin fragment F(ab\u2019)2 against RBD potently neutralizes SARS-CoV-2 in vitro"],"prefix":"10.1016","volume":"182","author":[{"given":"Xiaoyan","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejiong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijuan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengfu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104868_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2019.04.008","article-title":"Convalescent plasma therapy for persistent hepatitis E virus infection","volume":"71","author":"Ankcorn","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104868_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(14)71072-2","article-title":"Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')(2) fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study","volume":"15","author":"Bal","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104868_bib3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/infdis\/jiy199","article-title":"Anti-ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with Ebola virus disease","volume":"218","author":"Brown","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104868_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104868_bib5","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2020.104868_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004386","article-title":"Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera","volume":"10","author":"de Alwis","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2020.104868_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2009.07.018","article-title":"Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity","volume":"393","author":"Du","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2020.104868_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.antiviral.2020.104868_bib9","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1126\/science.aam7260","article-title":"Structural basis for antibody-mediated neutralization of Lassa virus","volume":"356","author":"Hastie","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2020.104868_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2020.104868_bib11","first-page":"31","article-title":"SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement","volume":"18","author":"Jaume","year":"2012","journal-title":"Hong Kong Med. J. = Xianggang yi xue za zhi"},{"key":"10.1016\/j.antiviral.2020.104868_bib12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/22221751.2020.1723441","article-title":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies","volume":"9","author":"Jiang","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.antiviral.2020.104868_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/viro.2000.0401","article-title":"Neutralization and enhancement of HIV-1 infection by sera from HIV-1 infected individuals who progress to disease at different rates","volume":"273","author":"Jolly","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2020.104868_bib14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/cid\/civ334","article-title":"The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States","volume":"61","author":"Kraft","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104868_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","article-title":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2020.104868_bib16","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1745-7254.2005.00210.x","article-title":"Preparation and development of equine hyperimmune globulin F(ab')2 against severe acute respiratory syndrome coronavirus","volume":"26","author":"Lu","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.antiviral.2020.104868_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12250-018-0009-2","article-title":"Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine","volume":"33","author":"Luo","year":"2018","journal-title":"Virol. Sin."},{"key":"10.1016\/j.antiviral.2020.104868_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1128\/jvi.64.1.113-119.1990","article-title":"Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques","volume":"64","author":"Montefiori","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104868_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2018.06.002","article-title":"Novel neutralizing monoclonal antibodies against Junin virus","volume":"156","author":"Pan","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104868_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104666","article-title":"Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junin virus","volume":"174","author":"Pan","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104868_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004565","article-title":"A simple and novel strategy for the production of a pan-specific antiserum against elapid snakes of asia","volume":"10","author":"Ratanabanangkoon","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2020.104868_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ebiom.2017.04.010","article-title":"Intravenous immunoglobulin protects against severe pandemic influenza infection","volume":"19","author":"Rockman","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.antiviral.2020.104868_bib23","first-page":"2239","article-title":"Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases","volume":"15","author":"Ruggiero","year":"1986","journal-title":"Presse Med."},{"key":"10.1016\/j.antiviral.2020.104868_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20564","article-title":"Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice","volume":"540","author":"Sapparapu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2020.104868_bib25","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2020.104868_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007236","article-title":"Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2","volume":"14","author":"Song","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2020.104868_bib27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.antiviral.2020.104868_bib28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.virol.2016.10.005","article-title":"A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection","volume":"499","author":"Tai","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2020.104868_bib29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/104454904323145272","article-title":"Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB\/c mice","volume":"23","author":"Tang","year":"2004","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.antiviral.2020.104868_bib30","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2020.104868_bib31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.antiviral.2020.104868_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/vox.12926","article-title":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how","author":"Tiberghien","year":"2020","journal-title":"Vox Sang."},{"key":"10.1016\/j.antiviral.2020.104868_bib33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17460441.2019.1581171","article-title":"Broad-spectrum coronavirus antiviral drug discovery","volume":"14","author":"Totura","year":"2019","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.antiviral.2020.104868_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2020.104868_bib35","article-title":"Equine-Origin immunoglobulin fragments protect nonhuman primates from Ebola virus disease","volume":"93","author":"Wang","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104868_bib36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"1111","key":"10.1016\/j.antiviral.2020.104868_bib37","first-page":"12927","article-title":"Pivotal role of convalescent plasma in managing emerging infectious diseases","volume":"10","author":"Wong","year":"2020","journal-title":"Vox Sang."},{"key":"10.1016\/j.antiviral.2020.104868_bib38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1743-422X-11-82","article-title":"Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus","volume":"11","author":"Yip","year":"2014","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2020.104868_bib39","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jmv.25733","article-title":"Clinical trial analysis of 2019-nCoV therapy registered in China","volume":"92","author":"Zhang","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2020.104868_bib40","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jmv.25733","article-title":"Clinical trial analysis of 2019-nCoV therapy registered in China","volume":"92","author":"Zhang","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2020.104868_bib41","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1537-2995.2005.00179.x","article-title":"Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma","volume":"45","author":"Zhang","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.antiviral.2020.104868_bib42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41423-020-0385-z","article-title":"Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.antiviral.2020.104868_bib43","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for influenza A (H5N1) infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104868_bib44","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:34:06Z","timestamp":1759062846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220302825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":44,"alternative-id":["S0166354220302825"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104868","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.07.029884","asserted-by":"object"}]},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoglobulin fragment F(ab\u2019)2 against RBD potently neutralizes SARS-CoV-2 in vitro","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104868"}}